ArticleFrontiers in neurology
Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify factors associated with secondary generalization in patients with ocular-onset myasthenia gravis (OoMG) who were positive for anti-acetylcholine receptor (AChR) antibodies. Early identification of patients at higher risk of progression to generalized myasthenia gravis (gMG) is clinically relevant to optimize therapeutic strategies and improve long-term outcomes. Methods: We conducted a multicenter retrospective cohort study including patients with anti-AChR-positive OoMG recruited from three Italian neurology centers. Demographic, clinical, electrophysiological, and serological data were collected. Univariable and multivariable Cox regression analyses were performed to identify factors associated with disease generalization. Results: Among 85 patients, 40 (47.1%) developed gMG during follow-up. In univariable Cox regression, higher anti-AChR antibody titers (HR 3.37, 95% CI 1.53-7.43; Conclusion: Higher anti-AChR antibody titers and abnormal facial repetitive nerve stimulation were associated with an increased risk of secondary generalization in seropositive OoMG. Although these factors did not independently predict generalization in multivariable analysis, their combined assessment may support early clinical risk stratification. Larger prospective studies are warranted to validate these findings and refine prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.